881674-89-1

Basic information

• Product Name: 1H-Pyrrole-3-carboxylic acid, 5-bromo-1-[(3-chlorophenyl)sulfonyl]-4-methyl-, methyl ester
• CAS NO: 881674-89-1
• Molecular Formula: C13H11BrClNO4S
• Molecular Weight: 392.658
• Mol File: 881674-89-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1H-Pyrrole-3-carboxylic acid, 5-bromo-1-[(3-chlorophenyl)sulfonyl]-4-methyl-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrole-3-carboxylic acid, 5-bromo-1-[(3-chlorophenyl)sulfonyl]-4-methyl-, methyl ester(881674-89-1)
• EPA Substance Registry System: 1H-Pyrrole-3-carboxylic acid, 5-bromo-1-[(3-chlorophenyl)sulfonyl]-4-methyl-, methyl ester(881674-89-1)

Safety Data

• Hazardous Substances Data: 881674-89-1(Hazardous Substances Data)

Usage

Properties and specific content of 1H-Pyrrole-3-carboxylic acid, 5-bromo-1-[(3-chlorophenyl)sulfonyl]-4-methyl-, methyl ester

A chemical formula that indicates the compound is composed of 15 carbon atoms, 13 hydrogen atoms, 1 bromine atom, 1 chlorine atom, 1 nitrogen atom, and 4 oxygen atoms, as well as 1 sulfur atom.

Methyl ester derivative

1H-pyrrole-3-carboxylic acid
The compound is derived from 1H-pyrrole-3-carboxylic acid by replacing the carboxyl group (-COOH) with a methyl ester group (-COOCH3).

Bromo and sulfonyl substituents

Pyrrole ring
The pyrrole ring has a bromine atom and a sulfonyl group (-SO2-) attached to it, which can influence the compound's chemical reactivity and biological activity.

Pharmaceutical research

Potential lead compound
The compound is used in pharmaceutical research as a potential lead compound for the development of novel drugs due to its ability to target specific biological pathways.

Potential therapeutic applications

Anti-inflammatory or analgesic properties
The compound may have potential anti-inflammatory or analgesic properties based on its chemical structure, and it has been studied for its potential therapeutic applications.

Further research needed

Pharmacological and toxicological properties
Additional research is required to fully understand the compound's pharmacological and toxicological properties before it can be considered for clinical use.

Upstream product

• 881674-29-9 methyl 5-bromo-4-methyl-1H-pyrrole-3-carboxylate 
• 2888-06-4 3-chlorophenylsulfonyl chloride 

Downstream Products

• 881681-33-0 1-[(3-chlorophenyl)sulfonyl]-4-methyl-5-phenyl-1H-pyrrole-3-carbaldehyde 
• 881675-51-0 methyl 1-[(3-chlorophenyl)sulfonyl]-4-methyl-5-phenyl-1H-pyrrole-3-carboxylate 

Relevant articles and documents

Proton pump inhibitors

A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R 1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R 2 , R 3 and R 4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R 5 and R 6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof. or a prodrug thereof is provided.

PROTON PUMP INHIBITORS

Proton pump inhibitors which have excellent proton pumping activity and which can be converted in vivo into proton pump inhibitors to exhibit antiulcer effect and so on, containing compounds represented by the general formula (I) or salts thereof or prodrugs of the same: (I) wherein X and Y are each independently a free valency or a spacer whose main chain has 1 to 20 carbon atoms; R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; R2, R3 and R4 are each independently hydrogen, an optionally substituted hydrocarbon group, optionally substituted thienyl, optionally substituted benzo[b]thienyl, optionally substituted furyl, optionally substituted pyridyl, optionally substituted pyrazolyl, optionally substituted pyrimidinyl, acyl, halogeno, cyano, or nitro; and R5 and R6 are each independently hydrogen or an optionally substituted hydrocarbon group.